45,205 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Principal Financial Group Inc.

Principal Financial Group Inc. bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 45,205 shares of the company’s stock, valued at approximately $1,062,000. Principal Financial Group Inc. owned approximately 0.08% of Stoke Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Marshall Wace LLP lifted its position in shares of Stoke Therapeutics by 7.9% during the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock valued at $26,111,000 after acquiring an additional 168,771 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Stoke Therapeutics by 21.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after purchasing an additional 293,072 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Stoke Therapeutics by 7.9% during the second quarter. Geode Capital Management LLC now owns 972,921 shares of the company’s stock valued at $11,044,000 after purchasing an additional 70,935 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Stoke Therapeutics by 67.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 900,272 shares of the company’s stock valued at $21,156,000 after purchasing an additional 362,299 shares during the period. Finally, MPM Bioimpact LLC increased its stake in Stoke Therapeutics by 13.8% in the 2nd quarter. MPM Bioimpact LLC now owns 789,698 shares of the company’s stock worth $8,963,000 after purchasing an additional 95,710 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have commented on STOK. Guggenheim assumed coverage on shares of Stoke Therapeutics in a research note on Thursday, February 5th. They set a “buy” rating and a $60.00 price objective for the company. JPMorgan Chase & Co. boosted their price target on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Monday, November 3rd. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a research report on Monday, January 5th. HC Wainwright lifted their price objective on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, Wedbush boosted their target price on shares of Stoke Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.18.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $30.98 on Thursday. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $38.69. The company has a market capitalization of $1.77 billion, a PE ratio of 46.24 and a beta of 1.10. The company’s 50 day moving average price is $31.54 and its 200 day moving average price is $27.33.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 13,430 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $32.27, for a total value of $433,386.10. Following the transaction, the director directly owned 49,124 shares of the company’s stock, valued at $1,585,231.48. This represents a 21.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Jonathan Allan sold 3,978 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $32.28, for a total value of $128,409.84. Following the sale, the general counsel directly owned 11,831 shares of the company’s stock, valued at $381,904.68. This trade represents a 25.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 58,302 shares of company stock valued at $1,826,430. Insiders own 9.50% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.